Prometheus Biosciences, Inc.
OPTIMIZED ANTI-TL1A ANTIBODIES
Last updated:
Abstract:
Described herein are humanized anti-TL1A antibodies and pharmaceutical compositions for the treatment of inflammatory bowel disease (IBD), such as Crohns Disease (CD) and ulcerative colitis (UC).
Status:
Application
Type:
Utility
Filling date:
24 Apr 2019
Issue date:
11 Mar 2021